Tuberculosis Infection

Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin

Testing Health Workers At Risk to Advance Our Understanding of TB Infection

Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention

Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis

Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service

Isoniazid-Related Hepatotoxicity in Clinical Practice: Incidence and Predictors

Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women

Immunization With BCG Vaccine to Prevent Tuberculosis Infection

Window Prophylaxis for Pediatric Tuberculosis Prevention Trial

Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam

Effects of Tuberculosis Infection on Development and Function of the Placenta

Collision of Three Global Pandemics: the Effect of Tuberculosis and HIV on the Epidemiological, Clinical, Virological and Immunological Trajectory of COVID-19 in Botswana and Namibia

Immunological Biomarkers in Tuberculosis Management

Analysis of Liver Injury Risk Factors in a Multiethnic Population Treated With Antituberculosis Drugs

Effect of Integrating Traditional Tuberculosis Care With Modern Health Care on Case Detection

Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy

Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years

Multicenter Italian Cohort Study on Tuberculosis in Pediatric Age